Capricor Therapeutics, Inc.

Capricor is a clinical-stage biotech built around Deramiocel (CAP-1002), a cell therapy for the cardiomyopathy that kills Duchenne muscular dystrophy patients. The stock is now a single-outcome trade: the FDA's PDUFA target date is August 22, tomorrow.

• The advisory-committee signal was decisively negative: the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 3-9 against effectiveness on July 29 — advisory recommendations aren't binding, but FDA typically follows them on efficacy questions, and this one was lopsided.
• The Lancet publication weakened the pivotal endpoint: the peer-reviewed HOPE-3 analysis revised the LVEF p-value from 0.04 to 0.09, meaning the trial's cardiac-function endpoint no longer clears the standard 5% statistical-significance threshold — a real drag on the regulatory case.
• The stock has already priced most of a bad outcome: down 86% year-to-date, sitting in the bottom 9% of its 52-week range, and roughly 73% below its 200-day moving average — combined with 15% short interest, the setup allows a violent squeeze if the FDA approves anyway.
• The corporate signal cuts against a base case of denial: management signed a 138-month lease for a 171,000-sq-ft manufacturing facility, contingent on FDA approval — real dollars committed to a positive path, though a lease is far cheaper than a rejected drug.

This is essentially a coin-flip trade priced 80%+ toward denial. The Aug 22 PDUFA either delivers an unlikely approval (that would cause a +100% move as shorts unwind and the FDA-lease optionality vests) or a Complete Response Letter (that would take the stock to fresh lows as securities class actions accelerate). Position accordingly — this is not a fundamentals-first setup.